Publications by authors named "Steven Chun-Min Shih"
Article Synopsis
- Multiple myeloma (MM) is an incurable cancer affecting older adults, and its prevalence is expected to rise in the next decade due to an aging population.
- Recent advancements in treatment, including immunomodulatory drugs and monoclonal antibodies, have improved outcomes, with ongoing innovations in immunotherapy anticipated for the future.
- This review highlights the importance of assessing patient frailty, outlines treatment goals and options for both newly diagnosed and relapsed MM, and discusses knowledge gaps for improving care in older adults.
Multiple myeloma (MM) is an incurable plasma cell malignancy. In the context of the current standard of care therapies in Canada, outcomes among patients with relapsed/refractory multiple myeloma (RRMM), particularly those with triple-class (or more) refractory disease remain poor. Immunotherapies have significantly changed the treatment landscape of MM.
View Article and Find Full Text PDF